author-photo

Katja Weisel

University of Hamburg
University of Tübingen

435

Papers

9126

Citations

Citation Trend

Filter By

Papers (435) Sort By

Journal Conference Others

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: Frailty subgroup analysis of MAIA

2022
Show All
- Source
- Cite
- Save
Citations (0)
CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (ciltacel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation.

2021 Onkologie
Show All
- Source
- Cite
- Save
Citations (0)
Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
CD19+ B Lymphocytes Are Predictive for Anti-Sars-Cov-2 Vaccination Response in Multiple Myeloma Patients

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
P-224: Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)